MRGM Research aims to decipher the molecular mechanisms laying at the root of the physiopathology of rare diseases and make our findings worth for patients.
HRAS germline mutations impair LKB1/AMPK signaling and mitochondrial homeostasis in Costello syndrome models https://sbm.u-bordeaux.fr/actualites/mise-en-lumiere-de-la-publication-hras-germline-mutations-impair-lkb1ampk-signaling-and-mitochondrial-homeostasis-costello-syndr
Inserm's Science and Society department has published testimonies of participatory research on the Inserm website. https://www.inserm.fr/nos-recherches/recherche-participative/ These exchanges are rich in lessons on collaborative research…
Didier Lacombe: CSS2 - Cancerology, genetic diseases. Rodrigue Rossignol: CSS3 – Physiology and physiopathology of large systems.
Our research unit, the MRGM (Rare Diseases: Genetics and Metabolism), was evaluated by HCERES in February 2021.
The MRGM invites José Antonio Enríquez, a world leading scientist of the mitochondrial research field, to give a lecture on his exciting recent work.
Sophie Javerzat, Karine Lecommandoux and Agata Ars, Professor at the University of Bordeaux, Administrative Assistant and Technical Assistant, respectively, have recently joined the MRGM. Warm welcome!
A one-year engineer position is available starting January 2020 to join Garaude's group to investigate innate immune-mediated regulation of mitochondrial metabolism.
An additional regulator of mitochondrial bioenergetics discovered by Rossignol’s group: the protein EIF3F stimulates OXPHOS through AMPK. A ChipSeq/Proteomics analysis.
Caroline Rooryck-Thambo and Giovanni Bénard, two principal investigators at MRGM just have been promoted!
Jean-Paul Lasserre is an associate professor at the University of Bordeaux and has recently joined the MRGM team. He will notably develop yeast models for rare diseases.
Rare Diseases: Genetics and Metabolism 